TH17 CELLS IN CLASSICAL HODGKIN LYMPHOMA ARE SUPPRESSED VIA THE PD1-PDL1 AXIS AND MAY PLAY AN IMPORTANT ROLE IN THE ACTION OF PD1 CHECKPOINT INHIBITORS
EHA Learning Center, Joseph Taylor, 214533
EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN 15 PEDIATRIC REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS.
EHA Learning Center, Jing PAN, 214537
LUSPATERCEPT INHIBITS PSMAD2/3 SIGNALING AND PROMOTES ERYTHROID MATURATION THROUGH A GATA1 DEPENDENT MECHANISM
EHA Learning Center, Pedro Martinez, 214542
IL1RAP POTENTIATES MULTIPLE ONCOGENIC SIGNALING PATHWAYS IN AML
EHA Learning Center, Kelly Mitchell, 214602
REDUCED FIBROBLASTIC RETICULAR CELL EXPRESSION OF TISSUE-RESTRICTED ANTIGENS IMPAIRS PERIPHERAL REGULATION OF SELF-REACTIVE T CELLS DURING ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Simone Dertschnig, 214605
PLATELET ADHESION UNDER FLOW CONDITION IS SIGNIFICANTLY AFFECTED BY HEMATOCRIT LEVELS IN POLYCYTHEMIA VERA PATIENTS
EHA Learning Center, Sara gamba, 214607
Genetics of classical Hodgkin Lymphoma (cHL)
EHA Learning Center, Enrico Tiacci, 219158
Optimization of the first line treatment in HD
EHA Learning Center, Pauline Brice, 219159
New strategies for relapsed/refractory Hodgkin lymphoma
EHA Learning Center, John Kuruvilla, 219160
Immunotherapy in myeloma: Why, when and how?
EHA Learning Center, Niels van de Donk, 219162
Optimal sequencing in the management of relapsed/refractory myeloma patients
EHA Learning Center, Philippe Moreau, 219163
Education session - MM: Chair
EHA Learning Center, Michel Delforge, 219164
Inherited predisposition to MDS/AML
EHA Learning Center, Jude Fitzgibbon, 219166
Recent developments in immunotherapy in AML
EHA Learning Center, Marion Subklewe, 219167
Epigenetic therapy and beyond in AML
EHA Learning Center, Andrew Wei, 219168
Pathogenesis of cancer-associated thrombosis
EHA Learning Center, Nigel Mackman, 219396
Clinical prediction scores for venous thromboembolism in patients with a hematological malignancy
EHA Learning Center, Nick van Es, 219397
Cancer-associated thrombosis - Which lessons for the hematologist?
EHA Learning Center, Simon Noble, 219398
Pathogenesis of CLL: the view from the lymph node
EHA Learning Center, Adrian Wiestner, 219093
Translating genetic and epigenetic knowledge into clinical utility
EHA Learning Center, Richard Rosenquist, 219094
Current role of chemotherapy free drug combinations for chronic lymphocytic leukemia
EHA Learning Center, Michael Hallek, 219095
Deregulation of cell signaling in marginal zone lymphoma
EHA Learning Center, Ming Qing Du, 219139
Marginal zone lymphoma: Differentiation among pathologically challenging entities
EHA Learning Center, Maurilio Ponzoni, 219140
From antibiotics to ibrutinib: An array of treatment modalities
EHA Learning Center, Catherine Thieblemont, 219141
Methods to detect minimal residual disease
EHA Learning Center, Torsten Haferlach, 219143
Clinical implications of minimal residual disease
EHA Learning Center, Johannes Jacobus Cornelissen, 219144
Preventing relapse of transplant
EHA Learning Center, Charles Craddock, 219145
Iron-sulfur protein biogenesis in health and disease
EHA Learning Center, Roland Lill, 219147
Congenital sideroblastic anemia: Iron and heme lost in mitochondrial translation
EHA Learning Center, Mark Fleming, 219148
Potential perils of iron supplementation in low income countries
EHA Learning Center, Andrew Prentice, 219149
Clinical and laboratory evaluation of acute blood loss and hemorrhagic shock
EHA Learning Center, Augusto Federici, 219150
Update on the pathophysiology and management of acute trauma hemorrhage and trauma-induced coagulopathy
EHA Learning Center, Marc Maegele, 219151
Transfusion in patients with acute major blood loss: Evidence when, for whom and what products are best
EHA Learning Center, Jaap Jan Zwaginga, 219152
INTEGRATIVE ANALYSIS OF GENOMIC DATA REPOSITIONS THE USE OF 5’-AZACYTIDINE AND DECITABINE IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATMENT
EHA Learning Center, Maria Rosaria Sapienza, 214630
LOSS OF TET2 FOLLOWED BY ACQUISITION OF ACTIVATING KRAS MUTATION LEADS TO COOPERATIVE MALIGNANT MYELOPROLIFERATION THROUGH AMPLIFICATION OF RAS SIGNALING IN A DOSE- AND TIME-DEPENDENT MANNER
EHA Learning Center, Matthew Miller, 214631
5-AZACYTIDINE ENHANCES THE ANTI-LEUKEMIC ACTIVITIY OF IDH1 INHIBITOR BAY 1436032 IN VIVO IN IDH1 MUTANT ACUTE MYELOID LEUKEMIA
EHA Learning Center, Anuhar Chaturvedi, 214632
EPIGENOMIC ANALYSIS REVEALS STEM CELL-LIKE RELAPSE SIGNATURE IN PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Learning Center, Caroline Wiggers, 214648
COMBINATORIAL CSF3R AND RUNX1 MUTATIONS INVOLVED IN THE LEUKEMIC PROGRESSION OF SEVERE CONGENITAL NEUTROPENIA CONFER A G-CSF-DEPENDENT PREMALIGNANT STATE IN MICE TERMINATING IN G-CSF INDEPENDENT AML
EHA Learning Center, Patricia Olofsen, 214649
IDENTIFYING NEW DISEASE GENES IN FAMILIAL MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA
EHA Learning Center, Ana Rio-Machin, 214650
CDK8 DEGRADATION - PREPARING THE GROUND FOR MTOR INHIBITION IN BCR/ABL+ ALL
EHA Learning Center, Ingeborg Menzl, 214657
CIRCULAR RNAOME VARIATION IN NORMAL HEMATOPOIESIS AND MLL REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Stefania Bortoluzzi, 214658
INTEGRATED GENETIC AND EPIGENETIC ANALYSIS ELUCIDATED EXPRESSION AND METHYLATION PROFILES OF ACUTE LYMPHOBLASTIC LEUKEMIA IN DOWN SYNDROME
EHA Learning Center, Yasuo Kubota, 214659
ENHANCED EFFICACY OF THE SYK INHIBITOR ENTOSPLETINIB AND VINCRISTINE IN KMT2A-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Sarah Tasian, 214660
NOVEL TARGETED THERAPIES FOR RESISTANT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Sanil Bhatia, 214661
DEHYDROPEPTIDASE 1 ENHANCED THE GROWTH AND SURVIVAL OF LEUKEMIA CELLS IN VIVO AND IDENTIFIED A HIGH RISK OF RELAPSE IN PATIENTS WITH COMMON B-CELL ALL
EHA Learning Center, Jia-Min Zhang, 214662
TARGETING WNT10B*R-MEDIATED AUTOCRINE WNT SIGNALING ACTIVATION IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Adriana Cassaro, 214663
MIR-451 IS A NEW BIOMARKER THAT IDENTIFIES ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH NAMPT INHIBITORS
EHA Learning Center, Keren shichrur, 214664
NOVEL PROGNOSTIC MARKER ARID5B LOW EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Chunhua song, 214665
NOVEL IKAROS TARGET RAG1 HIGH EXPRESSION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Zheng Ge, 214666
S100A16 INHIBITED PROLIFERATION AND PROMOTED APOPTOSIS THROUGH REGULATION OF ERK PATHWAY IN B CELL ALL
EHA Learning Center, Jing Zhang, 214667
MELATONIN INHIBITS MLL-REARRANGED LEUKEMIA VIA RBFOX3/HTERT AND NF-ΚB/COX-2 SIGNALING PATHWAYS
EHA Learning Center, Yan-Lai Tang, 214668
INVESTIGATING THE SYNERGISM BETWEEN CHK1 AND WEE1 PROTEINS INHIBITION IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Andrea Ghelli Luserna Di Rora, 214669
AN UPDATED ANALYSIS OF TISAGENLECLEUCEL IN PEDIATRIC/YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN A US MULTICENTER CLINICAL TRIAL (ENSIGN)
EHA Learning Center, Shannon Maude, 214670
PHASE I STUDY OF UCART19, AN ALLOGENEIC ANTI-CD19 CAR T-CELL PRODUCT, IN HIGH RISK PEDIATRIC PATIENTS WITH CD19+ RELAPSED/REFRACTORY (R/R) B-CELL ALL: PRELIMINARY RESULTS OF PALL STUDY
EHA Learning Center, Waseem Qasim, 214671
CHARACTERISTICS AND OUTCOMES OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA RELAPSING POST-ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION IN THE PROSPECTIVE UKALL14 TRIAL (ISRCTN 665421317).
EHA Learning Center, Anna Castleton, 214672
INOTUZUMAB OZOGAMICIN TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS FROM INO-VATE BY BONE MARROW BLAST PERCENTAGE
EHA Learning Center, David Marks, 214673
UCART19, AN ALLOGENEIC ANTI-CD19 CAR T-CELL PRODUCT, IN HIGH RISK ADULT PATIENTS WITH CD19+ RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF PHASE I CALM STUDY
EHA Learning Center, Reuben Benjamin, 214674
LONG-TERM SURVIVAL OF ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) AFTER TREATMENT WITH BLINATUMOMAB AND SUBSEQUENT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Nicola Goekbuget, 214675
RE-THINKING THE PROGNOSTIC RELEVANCE OF A CD20 EXPRESSION CUT-OFF OF 20% IN ACUTE LYMPHOBLASTIC LEUKAEMIA: INITIAL RESULTS FROM THE UKALL14 TRIAL
EHA Learning Center, Katharine Bailey, 214676
IMPROVEMENT OF PATIENT-REPORTED QUALITY OF LIFE FOLLOWING TISAGENLECLEUCEL INFUSION IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Andre Baruchel, 214677
OUTCOMES WITH INOTUZUMAB OZOGAMICIN IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Giovanni Martinelli, 214678
IMPACT OF MINIMAL RESIDUAL DISEASE STATUS IN CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN IN THE PHASE 3 INO-VATE TRIAL
EHA Learning Center, Nicola Gökbuget, 214679
EXTENSIVE SAFETY PROFILE OF INOTUZUMAB OZOGAMICIN IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS ENROLLED IN THE PHASE 3 INO-VATE TRIAL
EHA Learning Center, Daniel DeAngelo, 214680
BLINATUMOMAB AND TYROSINE KINASE INHIBITORS COMBINATION IN RELAPSED/REFRACTORY ACUTE LYMPHOBALTIC LEUKEMIA: PRIMARY RESULTS AND LATE EVENTS
EHA Learning Center, Andrey Sokolov, 214681
CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PEDIATRIC/ADOLESCENT/YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANT IN CR1
EHA Learning Center, Peter Bader, 214682
INDIRECT TREATMENT COMPARISON OF BLINATUMOMAB VS INOTUZUMAB OZOGAMICIN FOR TREATING ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING ZERO OR ONE PRIOR SALVAGE THERAPY
EHA Learning Center, Ze Cong, 214683
LONG TERM OUTCOME OF 138 ALO TRANSPLANTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ON A SINGLE TRANSPLANT CENTER IN SPAIN
EHA Learning Center, Irati Ormazabal Velez, 214684
ROBUST IN VIVO SYNERGY BETWEEN THE ANTI-CD33 ADC, IMGN779 AND THE FLT3 INHIBITOR QUIZARTINIB IN HUMAN FLT3-ITD AML MODELS.
EHA Learning Center, Krystal Watkins, 214685
NOVEL MUTATIONS AND TRANSLOCATIONS INVOLVING NUCLEOPHOSMIN (NPM1) GENE IN ACUTE MYELOID LEUKEMIA (AML) AND LEADING TO ABERRANT CYTOPLASMIC NPM1
EHA Learning Center, Maria Paola Martelli, 214686
THE LSC17 SCORE ALLOWS RISK STRATIFICATION IN PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Learning Center, Nicolas Duployez, 214687
MUTATION PROFILE AND BENEFIT OF GEMTUZUMAB OZOGAMICIN IN ACUTE MYELOID LEUKEMIA PATIENTS TREATED IN THE ALFA-0701 TRIAL
EHA Learning Center, Elise Fournier, 214688
MOLECULAR PATHOGENESIS OF DISEASE PROGRESSION IN MLL-REARRANGED AML
EHA Learning Center, Hideki Makishima, 214689
GENOMIC CHARACTERISTICS OF ACUTE ERYTHROID LEUKEMIA
EHA Learning Center, June Takeda, 214690
FUNCTIONAL PROTEOMICS ANALYSIS OF AML-RELATED NUP98-FUSION PROTEIN INTERACTOMES
EHA Learning Center, Stefan Terlecki-Zaniewicz, 214691
THE PNT DOMAIN OF ERG REGULATES HEMATOPOIETIC STEMNESS, YET IS NOT ESSENTIAL FOR ERG INDUCED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Eitan Kugler, 214692
FUNCTIONAL ANALYSIS OF EPIGENETIC AND TRANSCRIPTOMIC EFFECTS OF CEBPA MUTATIONS IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Elizabeth Heyes, 214693
DETECTION OF MEASURABLE RESIDUAL DISEASE (MRD) BY ULTRADEEP NEXT GENERATION SEQUENCING (NGS) IS HIGHLY PREDICTIVE OF OUTCOME IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Nikhil Patkar, 214694
PREFERENTIAL IN VITRO AND IN VIVO INDUCTION OF ENDOGENOUS RETROVIRUS TRANSCRIPTION FROM A MONOALLELIC CHROMOSOME 7Q IN DECITABINE (DAC) TREATED AML BLASTS
EHA Learning Center, Gabriele Greve, 214695
NOVEL DEEP TARGETED SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID
 LEUKEMIA
EHA Learning Center, Maria Esther Onecha De La Fuente, 214696
A SYSTEMATIC EVALUATION OF PROGNOSTIC GENE EXPRESSION SIGNATURES IN 1208 ACUTE MYELOID LEUKEMIA PATIENTS REVEALS NOVEL INSIGHTS FOR FUTURE RESEARCH AND CLINICAL APPLICATION
EHA Learning Center, Dominik Beck, 214697
AN ARTIFICIAL NEURAL NETWORK-BASED APPROACH IDENTIFIES A POWERFUL 3-GENE PREDICTOR OF ADVERSE PROGNOSIS IN ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Sarah Wagner, 214698
PROFILING AND FUNCTIONAL ANALYSIS OF CIRCULAR RNAS IN ACUTE PROMYELOCYTIC LEUKEMIA AND THEIR DYNAMIC REGULATION DURING ALL-TRANS RETINOIC ACID TREATMENT
EHA Learning Center, Shufen Li, 214699
PML-RARA INTERACTS WITH NRF2, INHIBITS ITS ACTIVITY AND INCREASES THE SENSITIVITY OF ACUTE PROMYELOCITIC LEUKEMIA CELLS TO ASCORBATE
EHA Learning Center, Nelida Noguera, 214700
A POSSIBLE FIRST TIER SCREENING TEST TO DETECT TRANSLOCATIONS IN LEUKEMIAS USING TARGETED LOCUS AMPLIFICATION
EHA Learning Center, Eva Van Den Berg-De Ruiter, 214701
FUNCTIONAL EVALUATION AND MECHANISM RESEARCH OF KEL AND CIRC-KEL IN AEL
EHA Learning Center, Hui Jin, 214702
MOLECULAR PROFILES IN AML PATIENTS OLDER THAN 70 YEARS OF AGE
EHA Learning Center, Montserrat Hoyos Colell, 214704
COMPARISON OF WHOLE GENOME ANALYSIS APPROACHES FOR DETECTION OF MAJOR CHROMOSOMAL ABERRATIONS USING A DIVERSE SET OF LEUKEMIA PATIENTS
EHA Learning Center, Sven Twardziok, 214705
SOMATIC MUTATIONS IN RELAPSED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Samuli Eldfors, 214706
EXPRESSION OF PIWI-INTERACTING RNAS (PIRNAS) AND ITS PROGNOSTIC IMPLICATION IN ACUTE MYELOID LEUKEMIA (AML): A 3-PIRNA SCORING SYSTEM PREDICTS PROGNOSIS IN AML PATIENTS
EHA Learning Center, Ta Yu, 214707
BASOPHIL-LINEAGE COMMITMENT IN ACUTE PROMYELOCYTIC LEUKEMIA PREDICTS FOR SEVERE BLEEDING AFTER STARTING THERAPY
EHA Learning Center, Alberto Orfao, 214708
RECURRENCE OF THE 8Q24 REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM AND ITS ASSOCIATION WITH IMMUNOBLASTOID CYTOMORPHOLOGY, MYC EXPRESSION, AND DRUG RESPONSE
EHA Learning Center, Kana Sakamoto, 214709
COMBINATION OF FLT3 INHIBITOR QUIZARTINIB AND MDM2 INHIBITOR MILADEMETAN RESULTS IN GREATER PRE-CLINICAL ANTI-LEUKEMIC ACTIVITY IN FLT3-ITD MUTANT/P53 WILD-TYPE ACUTE MYELOID LEUKEMIA MODELS
EHA Learning Center, Michael Andreeff, 214710
A GROUP OF EMA-APPROVED IMMUNOMODULATORS TARGETS AML STEM CELLS BY SABOTAGING THE CELLULAR RECYCLING MACHINERY
EHA Learning Center, Josep Maria Cornet Masana, 214711
EXPLORING ALTERNATIVE TREATMENTS TO IMPROVE OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Katrina Lappin, 214712
ADDITION OF CRENOLANIB TO STANDARD INDUCTION AND CONSOLIDATION THERAPIES IMPROVED LONG-TERM OUTCOMES IN NEWLY DIAGNOSED FLT3-MUTANT AML PATIENTS ≤ 60 YEARS OLD
EHA Learning Center, Roland B. Walter, 214713
COMBINATION OF IDARUBICIN, CYTARABINE AND CLADRIBINE AS INDUCTION REGIMEN FOR UNTREATED ADULT AML AGED 60 OR YOUNGER: A PHASE III RANDOMIZED CLINICAL TRIAL
EHA Learning Center, Jia Chen, 214714
REASSESSING THE PROGNOSTIC SIGNIFICANCE OF RECURRING CHROMOSOMAL ABNORMALITIES AND FLT3-ITD IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION: AN ALWP/EBMT ANALYSIS
EHA Learning Center, Jonathan Canaani, 214715
DECITABINE IN DAY TO DAY PRACTICE IN UNTREATED AML, RISK FACTORS AND COMPARISON WITH DACO16
EHA Learning Center, Adolfo De La Fuente, 214717
INITIAL PHASE 1 RESULTS OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS
EHA Learning Center, Paresh Vyas, 214718
IMPACT OF CONCOMITANT EXPRESSION OF CD200 AND BCL2 ON OUTCOME OF ACUTE MYELOID LEUKEMIA
EHA Learning Center, Mario Tiribelli, 214719

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings